Abbott Next Generation Drug Eluting Stent 48mm Study

NACompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

June 17, 2020

Primary Completion Date

October 5, 2022

Study Completion Date

September 17, 2023

Conditions
Coronary Artery Disease
Interventions
DEVICE

ABT NG DES 48 EECSS

Each participant will receive ABT NG DES 48 EECSS with appropriate diameter

Trial Locations (25)

112

Cheng Hsin General Hospital, Taipei

333

Chang Gung Memorial Hospital, Linkou District

2065

Royal North Shore Hospital, St Leonards

2170

Liverpool Hospital, Liverpool

4032

The Prince Charles Hospital, Chermside

10002

National Taiwan University Hospital, Taipei

10019

Mount Sinai Hospital, New York

17105

Pinnacle Health System, Harrisburg

29605

Greenville Health System, Greenville

32605

The Cardiac & Vascular Institute Research Foundation, LLC, Gainesville

32610

Shands at the University of Florida, Gainesville

38801

North Mississippi Medical Center, Tupelo

43608

St. Vincent Mercy Medical Center, Toledo

45219

The Lindner Center, Cincinnati

55407

Minneapolis Heart Institute, Minneapolis

59802

St. Patrick Hospital, Missoula

67214

Via Christi Regional Medical Center - St. Francis Campus, Wichita

67226

Cardiovascular Research Institute of Kansas, Wichita

75093

The Heart Hospital Baylor Plano, Plano

75226

Baylor Scott & White Heart & Vascular Hospital, Dallas

83301

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City

85258

HonorHealth, Scottsdale

90404

UCLA Medical Center Santa Monica, Santa Monica

92037

Scripps Memorial Hospital - La Jolla, La Jolla

02114

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
lead

Abbott Medical Devices

INDUSTRY

NCT04282148 - Abbott Next Generation Drug Eluting Stent 48mm Study | Biotech Hunter | Biotech Hunter